AU2018342751B2 - Selective P2X3 modulators - Google Patents

Selective P2X3 modulators Download PDF

Info

Publication number
AU2018342751B2
AU2018342751B2 AU2018342751A AU2018342751A AU2018342751B2 AU 2018342751 B2 AU2018342751 B2 AU 2018342751B2 AU 2018342751 A AU2018342751 A AU 2018342751A AU 2018342751 A AU2018342751 A AU 2018342751A AU 2018342751 B2 AU2018342751 B2 AU 2018342751B2
Authority
AU
Australia
Prior art keywords
selective
antagonist
alkyl
receptor antagonism
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018342751A
Other languages
English (en)
Other versions
AU2018342751A1 (en
Inventor
Roberto Bellini
Susan E. Browne
Nathalie Chauret
Denis Garceau
Antonios Matzouranis
Kemal Payza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 3 Ltd filed Critical GlaxoSmithKline Intellectual Property No 3 Ltd
Publication of AU2018342751A1 publication Critical patent/AU2018342751A1/en
Application granted granted Critical
Publication of AU2018342751B2 publication Critical patent/AU2018342751B2/en
Assigned to BELLUS HEALTH COUGH INC. reassignment BELLUS HEALTH COUGH INC. Request for Assignment Assignors: BELLUS HEALTH COUGH INC., NEOMED INSTITUTE
Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED reassignment GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED Request for Assignment Assignors: BELLUS HEALTH COUGH INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
AU2018342751A 2017-09-18 2018-09-14 Selective P2X3 modulators Active AU2018342751B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762560077P 2017-09-18 2017-09-18
US62/560,077 2017-09-18
US15/936,316 2018-03-26
US15/936,316 US10111883B1 (en) 2017-09-18 2018-03-26 Selective P2X3 modulators
PCT/IB2018/001513 WO2019064079A2 (en) 2017-09-18 2018-09-14 SELECTIVE MODULATORS OF P2X3

Publications (2)

Publication Number Publication Date
AU2018342751A1 AU2018342751A1 (en) 2020-04-23
AU2018342751B2 true AU2018342751B2 (en) 2023-06-15

Family

ID=63894683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018342751A Active AU2018342751B2 (en) 2017-09-18 2018-09-14 Selective P2X3 modulators

Country Status (12)

Country Link
US (6) US10111883B1 (https=)
EP (2) EP3684368B8 (https=)
JP (1) JP7242681B2 (https=)
KR (1) KR102713354B1 (https=)
CN (1) CN111601601A (https=)
AU (1) AU2018342751B2 (https=)
CA (1) CA3076150C (https=)
ES (1) ES2969868T3 (https=)
IL (2) IL273348B2 (https=)
MX (1) MX2020002968A (https=)
SG (1) SG11202002460QA (https=)
WO (1) WO2019064079A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963702T3 (es) * 2018-10-05 2024-04-01 Shionogi & Co Medicina para tratar la tos crónica
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
HRP20250864T1 (hr) 2018-11-13 2025-09-26 Glaxosmithkline Intellectual Property (No. 3) Limited Kristalni oblici p2x3 modulatora metil (s)‑2‑((2‑(2,6‑difluoro‑4‑(metilkarbamoil)fenil)‑7‑metilimidazo[1,2‑a] piridin‑3‑il)metil)morfolin‑4‑karboksilata
KR102797127B1 (ko) * 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
JP7578602B2 (ja) * 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
CN112409331B (zh) * 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CN115427419B (zh) 2020-02-14 2026-04-21 葛兰素史密斯克莱知识产权(第3号)有限公司 P2x3拮抗剂的制备
EP4103564A4 (en) * 2020-02-14 2024-05-01 GlaxoSmithKline Intellectual Property (No.3) Limited P2X3 MODULATORS
MX2022013499A (es) 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
WO2021244634A1 (zh) * 2020-06-05 2021-12-09 武汉人福创新药物研发中心有限公司 咪唑并吡啶类化合物及其用途
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
US20230218661A1 (en) * 2022-01-10 2023-07-13 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx
US20240408131A1 (en) * 2020-07-06 2024-12-12 Sensory Cloud, Inc. Isotonic or hypertonic salt-based compositions
CN113912601B (zh) * 2020-07-10 2023-06-06 上海拓界生物医药科技有限公司 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途
KR20230051209A (ko) * 2020-08-13 2023-04-17 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 벤즈이미다졸 유도체, 이의 제조 방법 및 이의 의학적 용도
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
US20240293420A1 (en) * 2021-06-10 2024-09-05 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical composition, preparation, and preparation method therefor and use thereof
CN115043836B (zh) * 2021-08-20 2023-07-18 苏州璞正医药有限公司 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
CN120917022A (zh) 2023-03-23 2025-11-07 葛兰素史密斯克莱知识产权(第3号)有限公司 氘代p2x3调节剂
WO2026022326A1 (en) 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2777746A1 (en) * 2009-11-18 2011-05-26 Astrazeneca Ab Benzoimidazole compounds and uses thereof
CA2898665A1 (en) * 2013-01-31 2014-08-07 Neomed Institute Imidazopyridine compounds and their use as p2x purinoreceptor modulators
CA2921395A1 (en) * 2013-08-23 2015-02-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
CA2998742A1 (en) * 2015-09-29 2017-04-06 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
WO2018064135A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547343A4 (en) * 2010-03-19 2013-06-19 Univ Miami USE OF PURINERGER P2X RECEPTOR AGONISTS FOR INCREASED INSULIN DECISION IN PANCREAS BETA CELLS
EP3230281B1 (en) * 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2777746A1 (en) * 2009-11-18 2011-05-26 Astrazeneca Ab Benzoimidazole compounds and uses thereof
CA2898665A1 (en) * 2013-01-31 2014-08-07 Neomed Institute Imidazopyridine compounds and their use as p2x purinoreceptor modulators
CA2921395A1 (en) * 2013-08-23 2015-02-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
CA2998742A1 (en) * 2015-09-29 2017-04-06 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
WO2018064135A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods

Also Published As

Publication number Publication date
JP2020534355A (ja) 2020-11-26
US20200230148A1 (en) 2020-07-23
EP3684368A2 (en) 2020-07-29
US20220160724A1 (en) 2022-05-26
WO2019064079A2 (en) 2019-04-04
EP4331669A3 (en) 2024-05-01
CA3076150C (en) 2024-01-02
IL273348B2 (en) 2023-11-01
US10111883B1 (en) 2018-10-30
US20230248736A1 (en) 2023-08-10
SG11202002460QA (en) 2020-04-29
EP3684368A4 (en) 2021-05-26
AU2018342751A1 (en) 2020-04-23
KR20200092938A (ko) 2020-08-04
CA3076150A1 (en) 2019-04-04
IL273348B1 (en) 2023-07-01
IL273348A (en) 2020-05-31
EP3684368B8 (en) 2024-02-14
US20210322432A1 (en) 2021-10-21
JP7242681B2 (ja) 2023-03-20
KR102713354B1 (ko) 2024-10-02
ES2969868T3 (es) 2024-05-23
MX2020002968A (es) 2020-08-17
WO2019064079A3 (en) 2019-05-16
EP3684368B1 (en) 2024-01-03
US20210069201A1 (en) 2021-03-11
IL303257A (en) 2023-07-01
EP4331669A2 (en) 2024-03-06
CN111601601A (zh) 2020-08-28

Similar Documents

Publication Publication Date Title
AU2018342751B2 (en) Selective P2X3 modulators
JP4898062B2 (ja) アザ二環式カルバメートおよびアルファ−７ニコチン性アセチルコリンレセプターアゴニストとしてのその使用
JP2018522897A (ja) Ｂ型肝炎ウイルス感染の治療及び予防用の新規６，７−ジヒドロピリド［２，１−ａ］フタラジン−２−オン類
US10105373B2 (en) Fused triterpene compounds and uses thereof
EP3914589A1 (en) Methods of treating disease with magl inhibitors
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
WO2011014888A1 (en) Novel hedgehog inhibitors
EP3763718A1 (en) Substituted 3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, and methods for preparing and using same
US11718615B2 (en) Heterocyclic compounds and their application in medicine
US20120309990A1 (en) Processes for the Purification of Lubiprostone
CN118878544A (zh) 作为正粘病毒复制抑制剂用于治疗流感的化合物
CN102112469B (zh) 神经元nAChR的安静减敏剂及其使用方法
WO2007042668A1 (fr) Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique dans le traitement d' un dysfonctionnement lie au recepteur 1 de la mch
EP0237169B1 (en) 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates
JP4781362B2 (ja) ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
US10407406B2 (en) 2-halo-5-alkynyl-pyridyl nicotinic ligands
HK40036201A (en) Selective p2x3 modulators
JPH11504616A (ja) ジベンズ［ｃｄ，ｆ］インドール誘導体
US20170107173A1 (en) Therapeutic compounds and methods
WO2019232223A1 (en) Hsp90 beta selective inhibitors
CS226465B1 (cs) Deriváty 1-aryl-2-(3,4-dihydroxyfenyl)ethylaminů a jejich soli
FR2486801A1 (fr) Compositions pharmaceutiques a base de pyridoindoles
HK1065537A1 (zh) 作为抗抑郁药的异恶唑啉衍生物

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BELLUS HEALTH COUGH INC.

Free format text: FORMER APPLICANT(S): BELLUS HEALTH COUGH INC.; NEOMED INSTITUTE

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED

Free format text: FORMER OWNER(S): BELLUS HEALTH COUGH INC.